Targeting GRP receptor: Design, synthesis and preliminary biological characterization of new non-peptide antagonists of bombesin

We report the rational design, synthesis, and in vitro preliminary evaluation of a new small library of non-peptide ligands of Gastrin Releasing Peptide Receptor (GRP-R), able to antagonize its natural ligand bombesin (BN) in the nanomolar range of concentration. GRP-R is a transmembrane G-protein coupled receptor promoting the stimulation of cancer cell proliferation. Being overexpressed on the surface of different human cancer cell lines, GRP-R is ideal for the selective delivery to tumor cells of both anticancer drug and diagnostic devices. What makes very challenging the design of non -peptide BN analogues is that the 3D structure of the GRP-R is not available, which is the case for many membrane-bound receptors. Thus, the design of GRP-R ligands has to be based on the structure of its natural ligands, BN and GRP. We recently mapped the BN binding epitope by NMR and here we exploited the same spectroscopy, combined with MD, to define BN conformation in proximity of biological membranes, where the interaction with GRP-R takes place. The gained structural information was used to identify a rigid C-galactosidic scaffold able to sup-port pharmacophore groups mimicking the BN key residues' side chains in a suitable manner for binding to GRP-R. Our BN antagonists represent hit compounds for the rational design and synthesis of new ligands and mod-ulators of GRP-R. The further optimization of the pharmacophore groups will allow to increase the biological activity. Due to their favorable chemical properties and stability, they could be employed for the active receptor -mediated targeting of GRP-R positive tumors.

Automated summary

The study focuses on the rational design, synthesis, and preliminary evaluation of a new library of non-peptide ligands for Gastrin Releasing Peptide Receptor (GRP-R), which can antagonize its natural ligand bombesin (BN) at nanomolar concentrations. The research aims to develop hit compounds for the active targeting of GRP-R positive tumors through the selective delivery of anticancer drugs and diagnostic devices.